Pleural Effusion, Malignant Clinical Trial
Official title:
Management Of Malignant Pleural Effusion With Indwelling Pleural Catheter Versus Silver Nitrate Pleurodesis
The primary goal of this study is to compare well-defined pleural effusion management success outcomes in patients with malignant or paramalignant pleural effusions who were treated with Indwelling pleural catheter insertion compared with those treated with siver nitrate pleurodesis. It is also to demonstrate the effectiveness of silver nitrate pleurodesis. It is also important to evaluate frequent adverse events of silver nitrate pleurodesis in patients with malignant pleural effusion
Dyspnea is present in 50% of patients with malignant pleural effusion and quality of life is
significantly impaired.
Chemical pleurodesis using various sclerosing agents is accepted as a palliative therapy for
patients with recurrent, symptomatic, and malignant pleural effusions.
Silver nitrate solution (SNS) is a valid sclerosing agent that induce a caustic injury to the
mesothelium that results in an effective pleurodesis.
However, various clinical parameters and biochemical factors affect the success of
pleurodesis in symptomatic patients with MPE: symptoms and performance status of the patient,
daily fluid drainage, primary tumour, and mainly lung reexpansion following pleural fluid
evacuation.
The pleural injectate consists of 50 mL 0.5% SNS with 10mL of lidocaine (25mg/5mL).
An alternative treatment is intermittent or continuous drainage of the pleural fluid with a
chronic indwelling pleural catheter.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05693727 -
Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion
|
||
| Recruiting |
NCT05910112 -
Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
|
||
| Completed |
NCT03272997 -
The Value of PET-CT in Pleural Effusions
|
||
| Completed |
NCT03270215 -
The Added Value of CT Scanning in Patients With an Unilateral Pleural Effusion
|
||
| Completed |
NCT00099541 -
Non-small Cell Lung Cancer Registry
|
Phase 4 | |
| Recruiting |
NCT04844827 -
Pleural Carcinomatosis Tissue Banking
|
||
| Not yet recruiting |
NCT06436807 -
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
|
||
| Recruiting |
NCT05278975 -
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02407912 -
Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer
|
N/A | |
| Terminated |
NCT00316134 -
Multiple Biomarkers in Undiagnosed Pleural Effusion
|
N/A | |
| Not yet recruiting |
NCT06275178 -
Medical Thoracoscopy for Diagnosing Unexplained Pleural Effusion: a National Multicenter Retrospective Study
|
||
| Recruiting |
NCT04684459 -
Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis
|
Early Phase 1 | |
| Recruiting |
NCT04670562 -
Longitudinal Follow up of Patients With Pleural Effusion
|
||
| Not yet recruiting |
NCT02805062 -
Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy
|
N/A | |
| Completed |
NCT03276715 -
Prognostic Factors on Malignant Pleural Effusion
|
||
| Completed |
NCT03394105 -
Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Terminated |
NCT02702700 -
Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
|
Phase 1 | |
| Recruiting |
NCT02045121 -
Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management
|
N/A | |
| Completed |
NCT01670786 -
Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion
|
Phase 4 |